trending Market Intelligence /marketintelligence/en/news-insights/trending/QJr8Ro_sBGO3pY1SQ_gFgQ2 content esgSubNav
In This List

Medtronic acquires spinal cord therapy company Stimgenics

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Medtronic acquires spinal cord therapy company Stimgenics

Medtronic PLC said it acquired Stimgenics LLC, a Bloomington, Ill.-based privately held company developing a spinal cord stimulation therapy.

Financial terms of the deal were not disclosed in a Jan. 8 news release.

Stimgenics offers a spinal cord stimulation waveform known as Differential Target Multiplexed spinal cord stimulation. The therapy is delivered through Medtronic's Intellis platform for treating patients with chronic pain.

Dublin-based medical device company Medtronic said the acquisition is expected to be neutral to the company's fiscal 2020 EPS.